Literature DB >> 3512763

Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences.

J Sprent, M Schaefer, D Lo, R Korngold.   

Abstract

Highly purified populations of C57BL/6 (B6) L3T4+ and Lyt-2+ T cell subsets were compared for their capacity to exert alloreactivity to class I vs. class II H-2 differences in vivo. B6 Lyt-2+ cells responded strongly to the class I different mutant, bm1, as manifested by DNA synthesis in the spleen of irradiated mice followed by entry of blast cells into thoracic duct lymph, induction of splenomegaly in newborn mice, production of lethal GVHD in irradiated mice, and skin allograft rejection. By all of these parameters, B6 Lyt-2+ cells showed almost total unresponsiveness to the class II-different mutant, bm12. Reciprocal results were observed with B6 L3T4+ cells, these cells responding strongly against bm12 but not against bm1. In the case of purified T cell subsets from other strains, CBA/Ca and B10.BR L3T4+ cells both responded well to a full H-2 difference. Responses by Lyt-2+ cells from these strains were weaker, especially for CBA/Ca cells. The implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512763      PMCID: PMC2188064          DOI: 10.1084/jem.163.4.998

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Ability of H-2 regions to induce graft-vs-host disease.

Authors:  J Klein; C L Chiang
Journal:  J Immunol       Date:  1976-09       Impact factor: 5.422

2.  Correlation of graft-versus-host mortality and positive CML assay in the mouse.

Authors:  W L Elkins
Journal:  Transplant Proc       Date:  1976-09       Impact factor: 1.066

3.  Graft versus host reactions. Their natural history, and applicability as tools of research.

Authors:  M SIMONSEN
Journal:  Prog Allergy       Date:  1962

4.  Circulating T and B lymphocytes of the mouse. I. Migratory properties.

Authors:  J Sprent
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

5.  Surface immunoglobulin on H-2-activated T lymphocytes.

Authors:  J Sprent; L Hudson
Journal:  Transplant Proc       Date:  1973-12       Impact factor: 1.066

6.  Interaction of thymus lymphocytes with histoincompatible cells. I. Quantitation of the proliferative response of thymus cells.

Authors:  J Sprent; J F Miller
Journal:  Cell Immunol       Date:  1972-03       Impact factor: 4.868

7.  The H-2 major histocompatibility complex and the I immune response region: genetic variation, function, and organization.

Authors:  D C Shreffler; C S David
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

8.  Radiosensitivity of T and B lymphocytes. II. Effect of irradiation on response of T cells to alloantigens.

Authors:  J Sprent; R E Anderson; J F Miller
Journal:  Eur J Immunol       Date:  1974-03       Impact factor: 5.532

9.  Graft-versus-host reactions across different regions of the H-2 complex of the mouse.

Authors:  J Klein; J M Park
Journal:  J Exp Med       Date:  1973-05-01       Impact factor: 14.307

10.  Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  53 in total

1.  Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.

Authors:  T A Graubert; J F DiPersio; J H Russell; T J Ley
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 2.  T-cell subsets, bm mutants, and the mechanisms of allogeneic skin graft rejection.

Authors:  H Auchincloss; T Mayer; R Ghobrial; H J Winn
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Do L3T4+ T cells act as effector cells in protection against influenza virus infection.

Authors:  S Lightman; S Cobbold; H Waldmann; B A Askonas
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

Review 4.  Regulatory T cells in graft-versus-host disease.

Authors:  Benoît L Salomon; Muriel Sudres; José L Cohen
Journal:  Springer Semin Immunopathol       Date:  2006-06-29

5.  Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.

Authors:  Wilfried Reichardt; Christoph Dürr; Dominik von Elverfeldt; Eva Jüttner; Ulrike V Gerlach; Mayumi Yamada; Benjie Smith; Robert S Negrin; Robert Zeiser
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

6.  In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help.

Authors:  M A Rees; A S Rosenberg; T I Munitz; A Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Unregulated antigen-presenting cell activation by T cells breaks self tolerance.

Authors:  Jaeu Yi; Jisun Jung; Sung-Wook Hong; Jun Young Lee; Daehee Han; Kwang Soon Kim; Jonathan Sprent; Charles D Surh
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-31       Impact factor: 11.205

8.  Proliferation in vitro of Lyt2-,L3T4- thymocytes shows responsiveness to interleukin 1.

Authors:  G Chaudhri; I A Clark; R Ceredig
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

9.  Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.

Authors:  Robert Zeiser; Sawsan Youssef; Jeanette Baker; Neeraja Kambham; Lawrence Steinman; Robert S Negrin
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

10.  Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.

Authors:  Joseph H Chewning; Weiwei Zhang; David A Randolph; C Scott Swindle; Trenton R Schoeb; Casey T Weaver
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.